Linezolid in vitro: Mechanism and antibacterial spectrum

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue SUPPL. 2, 2003, Pages

  Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; EPEREZOLID; FOSFOMYCIN; GENTAMICIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; MESSENGER RNA; METICILLIN; MIKAMYCIN B; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; POLYPEPTIDE; POSIZOLID; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME RNA; RNA 23S; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL SURVIVAL; BACTERIOSTASIS; BACTEROIDES; BINDING SITE; CLINICAL TRIAL; COMPLEX FORMATION; DEVICE; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG RESEARCH; DRUG RESISTANCE; DRUG TRANSPORT; ENTEROCOCCUS; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HUMAN; IN VITRO STUDY; LONG TERM CARE; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; NONHUMAN; NUCLEOTIDE SEQUENCE; PASTEURELLA; PROKARYOTE; PROTEIN SYNTHESIS; REVIEW; RIBOSOME SUBUNIT; RISK FACTOR; STAPHYLOCOCCUS; STREPTOCOCCUS; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES;

EID: 0037764026     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Reacher, M. H., Shah, A., Livermore, D. M., Wale, M. C., Graham, C., Johnson, A. P. et al. (2000). Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. British Medical Journal 320, 213-6.
2. Woodford, N. & Livermore, D. M. (2001). Can we beat MRSA now we know its genome sequence? Lancet Infectious Diseases 1, 9-10.
3. Johnson, A. P., Warner, M., Broughton, K., James, D., Efsratiou, A., George, R. C. et al. (2001). Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000. British Medical Journal 322, 395-6.
4. European Antimicrobial Resistance Surveillance System (EARSS) Web site. (2002). Database published by RIVM/EARSS. [Online.] http://www.earss.rivm.nl (30 January 2003, date last accessed).
5. Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S. et al. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-3.
6. Oppenheim, B. A. (1998). The changing pattern of infection in neutropenic patients. Journal of Antimicrobial Chemotherapy 41, Suppl. D, 7-11.
7. Sahm, D. F., Marsilio, M. K. & Piazza, G. (1999). Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database USA. Clinical Infectious Diseases 29, 259-63.
8. Henwood, C. J., Livermore, D. M., Johnson, A. P., James, D., Warner, M. & Gardiner, A. (2000). Susceptibility of Gram-positive cocci in 25 UK hospitals to linezolid and other antimicrobial agents. Journal of Antimicrobial Chemotherapy 46, 931-40.
9. van Den, B. N., Ott, A., van Belkum, A., Kluytmans, J. A., Koeleman, J. G., Spanjaard, L. et al. (2000). Prevalence and determinants of fecal colonization with vancomycin-resistant Enterococcus in hospitalized patients in The Netherlands. Infection Control and Hospital Epidemiology 21, 520-4.
10. Kalin, M., Ortqvist, A., Almela, M., Aufwerber, E., Dwyer, R., Henriques, B. et al. (2000). Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. Journal of Infectious Diseases 182, 840-7.
11. Chen, D. K., McGeer, A., de Azavedo, J. C. & Low, D. E. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. New England Journal of Medicine 341, 233-9.
12. Song, J. H., Lee, N. Y., Ichiyama, S., Yoshida, R., Hirakata, Y., Fu, W. et al. (1999). Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clinical Infectious Diseases 28, 1206-11.
13. Doern, G. V., Ferraro, M. J., Brueggemann, A. B. & Ruoff, K. L. (1996). Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrobial Agents and Chemotherapy 40, 891-4.
14. Livermore, D. M. (2000). Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? Journal of Antimicrobial Chemotherapy 46, 347-50.
15. Slee, A. M., Wuonola, M. A., McRipley, R. J., Zajac, I., Zawada, M. J., Bartholomew, P. et al. (1987). Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrobial Agents and Chemotherapy 31, 1791-7.
16. Ford, C. W., Hamel, J. C., Stapert, D., Moerman, J. K., Hutchinson, D. K., Barbachyn, M. R. et al. (1997). Oxazolidinones: new antibacterial agents. Trends in Microbiology 5, 196-200.
17. Swaney, S. M., Aoki, H., Ganoza, M. C. & Shinabarger, D. L. (1998). The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrobial Agents and Chemotherapy 42, 3251-5.
18. Kloss, P., Xiong, L., Shinabarger, D. L. & Mankin, A. S. (1999). Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. Journal of Molecular Biology 294, 93-101.
19. Gemmell, C. G. & Ford, C. W. (2002). Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. Journal of Antimicrobial Chemotherapy 50, 665-72.
20. Johnson, A. P., Warner, M. & Livermore, D. M. (2000). Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. Journal of Antimicrobial Chemotherapy 45, 225-30.
21. Patel, R., Rouse, M. S., Piper, K. E. & Steckelberg, J. M. (1999). In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease 34, 119-22.
22. Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E. et al. (1996). In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrobial Agents and Chemotherapy 40, 839-45.
23. Gemmell, C. G. (2001). Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. Journal of Antimicrobial Chemotherapy 48, 47-52.
24. Jones, R. N., Ballow, C. H. & Biedenbach, D. J. (2001). Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagnostic Microbiology and Infectious Disease 40, 59-66.
25. Wise, R., Andrews, J. M., Boswell, F. J. & Ashby, J. P. (1998). The in-vitro activity of linezolid (U-100766) and tentative breakpoints. Journal of Antimicrobial Chemotherapy 42, 721-8.
26. Livermore, D. M., Mushtaq, S. & Warner, M. (2001). Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'. Journal of Antimicrobial Chemotherapy 48, 452-4.
27. Andrews, J. M. & BSAC Working Party on Susceptibility Testing. (2001). BSAC standardized disc susceptibility testing method. Journal of Antimicrobial Chemotherapy 48, Suppl. 1, 43-57.
28. Jones, R. N., Anderegg, T. R. & Deshpande, L. M. (2002). AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. Diagnostic Microbiology and Infectious Disease 43, 87-90.
29. Dresser, L. D. & Rybak, M. J. (1998). The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18, 456-62.
30. Swaney, S. M., Shinabarger, D. L., Schaadt, R. D. et al. (1998). Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA. In Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 1998. Abstract C-104, p. 98. American Society for Microbiology, Washington, DC, USA.
31. Zurenko, G. E., Todd, W. M., Hafkin, B., Meyers, B., Kauffman, C., Bock, J. et al. (1999). Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 1999. Abstract 848, p. 118. American Society for Microbiology, Washington, DC, USA.
32. Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K. & Quinn, J. P. (2001). Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179.
33. Johnson, A. P., Tysall, L., Stockdale, M. W., Woodford, N., Kaufmann, M. E., Warner, M. et al. (2002). Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. European Journal of Clinical Microbiology and Infectious Diseases 21, 751-4.
34. Auckland, C., Teare, L., Cooke, F., Kaufmann, M. E., Warner, M., Jones, G. et al. (2002). Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. Journal of Antimicrobial Chemotherapy 50, 743-6.
35. Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R. et al. (2001). Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy 45, 2154-6.
36. Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L. et al. (2001). Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-8.
37. Wilson, P., Andrews, J. A., Charlesworth, R., Walesby, R., Singer, M., Farrell, D. J. et al. (2003). Linezolid resistance in clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 51, 186-8.
38. Herrero, I. A., Issa, N. C. & Patel, R. (2002). Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. New England Journal of Medicine 346, 867-9.
39. Johnson, A. P., Warner, M. & Livermore, D. M. (2002). In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. Journal of Antimicrobial Chemotherapy 50, 89-93.
40. Thomasco, L. M., Weaver, E. A., Ochoada, J. M., Gadwood, R. C., Zurenko, G. E. & Ford, C. W. (2000). Synthesis and antibacterial activity of 2-aminomethyl-1,3,4-thiadiazole phenyl oxazolidinone thioamides. In Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 1829, p. 216. American Society for Microbiology, Washington, DC, USA.
41. Gordeev, M. F., Gadwood, R. C., Hackbarth, C. J. Lopez, C., Wu, C., Bore, R. et al. (2000). Combinatorial lead development of oxazolidinones: novel tetrahydro-4(2H)-thiopyran phenoyloxazolidinone sulfoxides and sulfones. In Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 1834, p. 217. American Society for Microbiology, Washington, DC, USA.
42. Ednie, L., Jacobs, M., Rattan, A. & Appelbaum, P. (2002). Anti-anaerobic activity of RBx 7644, a new oxazolidinone, compared with ten other agents. In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract F-1291, p. 208. American Society for Microbiology, Washington, DC, USA.
43. Cho, D., Lofland, D., Blais, J., Tangen, K., Cotter, D., Lomovskaya, O. et al. (2000). An efflux pump inhibitor (EPI), MC-04,124, enhances the activity of macrolides against Gram-negative bacteria. In Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 1497, p. 208. American Society for Microbiology, Washington, DC, USA.
44. Griffith, D., Lomovskaya, O., Lee, V. J. & Dudley, M. N. (2000). Potentiation of levofloxacin (Levo) by MC-02,595, a broad-spectrum efflux pump inhibitor (EPI) in mouse models of infection due to Pseudomonas aeruginosa (PA) with combinations of different Mex pump expression and a gyrA mutation. In Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 1496, p. 207. American Society for Microbiology, Washington, DC, USA.